Hyundai Bioscience Co (XKRX:048410) Change In Receivables : ₩-3,130 Mil (TTM As of Mar. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Hyundai Bioscience Co Change In Receivables?

Hyundai Bioscience Co's change in receivables for the quarter that ended in Mar. 2024 was ₩-4,923 Mil. It means Hyundai Bioscience Co's Accounts Receivable increased by ₩4,923 Mil from Dec. 2023 to Mar. 2024 .

Hyundai Bioscience Co's change in receivables for the fiscal year that ended in Dec. 2023 was ₩868 Mil. It means Hyundai Bioscience Co's Accounts Receivable declined by ₩868 Mil from Dec. 2022 to Dec. 2023 .

Hyundai Bioscience Co's Accounts Receivable for the quarter that ended in Mar. 2024 was ₩3,864 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Hyundai Bioscience Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 69.83.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Hyundai Bioscience Co's liquidation value for the three months ended in Mar. 2024 was ₩-261 Mil.

Hyundai Bioscience Co Change In Receivables Historical Data

The historical data trend for Hyundai Bioscience Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyundai Bioscience Co Change In Receivables Chart

Hyundai Bioscience Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

2,542.75

4,768.26

4,383.03

1,234.47

867.70

Hyundai Bioscience Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-925.28	523.40	-573.98	1,843.56	-4,923.43

Hyundai Bioscience Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-3,130 Mil.

Hyundai Bioscience Co (XKRX:048410) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Hyundai Bioscience Co's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	3864.262	/	5049.774	*	91
=	69.83

2. In Ben Graham's calculation of liquidation value, Hyundai Bioscience Co's accounts receivable are only considered to be worth 75% of book value:

Hyundai Bioscience Co's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3864.544	-	7319.834	+	0.75 * 3864.262	+	0.5 * 591.922
=	-261

Hyundai Bioscience Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Hyundai Bioscience Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyundai Bioscience Co (XKRX:048410) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyundai Bioscience Co Ltd (XKRX:048410) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

150 North-Ahyun Road, 3rd Floor Academic Cooperation Building, Ehwa Women’s University, Seodaemun-gu, Seoul, KOR

Website

http://www.hyundaibioscience.com

Hyundai Bioscience Co Ltd is a Korean biotechnology company. The company is engaged in developing and commercializing bio-fusion technology with the purpose of delivering active ingredients safely and efficiently to the body. It has developed Vitabrid CG, a biomaterial that binds vitamin C with bio-friendly mineral layers, which is a beneficial ingredient in skin brightening, anti-aging, and anti-inflammation; and Vitabrid C12, a premium skincare brand.

Hyundai Bioscience Co (XKRX:048410) Headlines

No Headlines